| Multiple Myeloma

Empliciti vs Velcade

Side-by-side clinical, coverage, and cost comparison for multiple myeloma.

Deep comparison between: Empliciti vs Velcade with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsVelcade has a higher rate of injection site reactions vs Empliciti based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Velcade but not Empliciti, including UnitedHealthcare

Category

Empliciti

Velcade

At A Glance

RouteIV infusion

FrequencyWeekly to every 4 weeks

ClassSLAMF7 antagonist

RouteSC or IV injection

FrequencyTwice weekly

ClassProteasome inhibitor

Indications

Multiple Myeloma

Multiple Myeloma
Carcinoma in situ of other and unspecified small intestine NOS

Dosing

Multiple Myeloma (with lenalidomide and dexamethasone) 10 mg/kg IV weekly for cycles 1 and 2 (28-day cycles), then 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity.

Multiple Myeloma (with pomalidomide and dexamethasone) 10 mg/kg IV weekly for cycles 1 and 2 (28-day cycles), then 20 mg/kg every 4 weeks until disease progression or unacceptable toxicity.

Multiple Myeloma 1.3 mg/m2 SC or IV; previously untreated: twice weekly (Days 1, 4, 8, 11) in cycles 1-4 then once weekly (Days 1, 8, 22, 29) in cycles 5-9 with melphalan and prednisone for 9 six-week cycles; relapsed: twice weekly (Days 1, 4, 8, 11) every 3 weeks as single agent or with dexamethasone.

Carcinoma in situ of other and unspecified small intestine NOS 1.3 mg/m2 IV twice weekly (Days 1, 4, 8, 11) for 2 weeks followed by a 10-day rest period, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP) for 6 three-week cycles.

Contraindications

—

Hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol, including anaphylactic reactions
Intrathecal administration

Drug Interactions

188View drug interactions

1286View drug interactions

Adverse Reactions

Most common (>=10%) Fatigue, diarrhea, pyrexia, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, pneumonia, pain in extremities, headache, vomiting, weight decreased, lymphopenia, cataracts, oropharyngeal pain

Serious Pneumonia, pyrexia, respiratory tract infection, anemia, pulmonary embolism, acute renal failure

Most common (>=10%) Nausea, diarrhea, fatigue, peripheral neuropathies, thrombocytopenia, vomiting, constipation, pyrexia, anorexia, anemia, headache, neutropenia, rash, paresthesia, dizziness, weakness

Serious Diarrhea, vomiting, pyrexia, nausea, dehydration, thrombocytopenia, pneumonia, dyspnea, peripheral neuropathies, herpes zoster

Postmarketing Cardiac tamponade, bilateral deafness, optic neuropathy, blindness, ischemic colitis, progressive multifocal leukoencephalopathy, herpes meningoencephalitis, posterior reversible encephalopathy syndrome, Guillain-Barre syndrome, demyelinating polyneuropathy, acute diffuse infiltrative pulmonary disease, Stevens-Johnson syndrome/toxic epidermal necrolysis, acute febrile neutrophilic dermatosis

Pharmacology

Elotuzumab is a humanized IgG1 monoclonal antibody that targets SLAMF7 on myeloma cells and natural killer (NK) cells, directly activating NK cells through the SLAMF7 pathway and mediating killing of myeloma cells via antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells; inhibition of this pathway disrupts homeostatic proteolysis, affecting multiple signaling cascades and leading to cell death in various cancer cell types including multiple myeloma.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Empliciti